A gene implicated in the causation of kidney disease

Duke University is seeking a company interested in commercializing a risk assessment test and/or a therapeutic product targeting a gene which has been implicated in Glomerulonephritis. Focal and segmental glomeruloschlerosis (FSGS) is a significant cause of end-stage renal disease worldwide, affecting 20% of patients on dialysis. Although it is understood that the primary target in FSGS is the glomerulus, knowledge of the pathogenesis of FSGS is incomplete and no consistently effective treatments exist. Therefore there is a need to identify genes and proteins which cause kidney disease. The technology under development is a series of reagents and methods based on the TRPC6 gene to more accurately and effectively diagnose and treat kidney disease.